User profiles for Debra Van Egeren

Debra Van Egeren

Postdoc, Stanford University School of Medicine
Verified email at stanford.edu
Cited by 1336

[PDF][PDF] Reconstructing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms

D Van Egeren, J Escabi, M Nguyen, S Liu, CR Reilly… - Cell stem cell, 2021 - cell.com
Some cancers originate from a single mutation event in a single cell. Blood cancers known
as myeloproliferative neoplasms (MPNs) are thought to originate when a driver mutation is …

Structure-based programming of lymph-node targeting in molecular vaccines

…, Y Zheng, GL Szeto, AV Li, B Huang, DS Van Egeren… - Nature, 2014 - nature.com
In cancer patients, visual identification of sentinel lymph nodes (LNs) is achieved by the
injection of dyes that bind avidly to endogenous albumin, targeting these compounds to LNs, …

[HTML][HTML] Microfluidic squeezing for intracellular antigen loading in polyclonal B-cells as cellular vaccines

GL Szeto, D Van Egeren, H Worku, A Sharei… - Scientific reports, 2015 - nature.com
B-cells are promising candidate autologous antigen-presenting cells (APCs) to prime
antigen-specific T-cells both in vitro and in vivo. However to date, a significant barrier to utilizing B-…

[HTML][HTML] Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein

D Van Egeren, A Novokhodko, M Stoddard, U Tran… - PloS one, 2021 - journals.plos.org
The spike protein receptor-binding domain (RBD) of SARS-CoV-2 is the molecular target for
many vaccines and antibody-based prophylactics aimed at bringing COVID-19 under control…

Risk of evolutionary escape from neutralizing antibodies targeting SARS-CoV-2 spike protein

D Van Egeren, A Novokhodko, M Stoddard, U Tran… - medRxiv, 2020 - medrxiv.org
As many prophylactics targeting SARS-CoV-2 are aimed at the spike protein receptor-binding
domain (RBD), we examined the risk of immune evasion from previously published RBD-…

[HTML][HTML] Reconstructing the lineage histories and differentiation trajectories of individual hematopoietic stem cells in JAK2-mutant myeloproliferative neoplasms

D Van Egeren, J Escabi, M Nguyen, S Liu, CR Reilly… - Blood, 2020 - Elsevier
*equal contribution, # co-corresponding authors Although the JAK2V617F mutation is the
most common MPN phenotypic driver mutation, the precise consequences of the mutation on …

[HTML][HTML] Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasms

D Van Egeren, B Kamaz, S Liu, M Nguyen… - Experimental …, 2022 - Elsevier
The JAK2–V617F mutation is the most common cause of myeloproliferative neoplasms.
Although experiments have revealed that this gain-of-function mutation is associated with …

[HTML][HTML] Controlling long-term SARS-CoV-2 infections can slow viral evolution and reduce the risk of treatment failure

D Van Egeren, A Novokhodko, M Stoddard, U Tran… - Scientific reports, 2021 - nature.com
The rapid emergence and expansion of novel SARS-CoV-2 variants threatens our ability to
achieve herd immunity for COVID-19. These novel SARS-CoV-2 variants often harbor …

[HTML][HTML] Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis

D Van Egeren, K Kohli, JL Warner, PL Bedard… - Scientific Reports, 2022 - nature.com
Patients with non-small cell lung cancer (NSCLC) who have distant metastases have a poor
prognosis. To determine which genomic factors of the primary tumor are associated with …

[HTML][HTML] Individually optimal choices can be collectively disastrous in COVID-19 disease control

M Stoddard, D Van Egeren, KE Johnson, S Rao… - BMC public health, 2021 - Springer
Background The word ‘pandemic’ conjures dystopian images of bodies stacked in the
streets and societies on the brink of collapse. Despite this frightening picture, denialism and …